nanobiotix.com (NBTX): Utang marang Ekuitas

Logo korporat perusahaan Nanobiotix Group (NBTX)

Nanobiotix S.A. (NBTX) is actively preparing breakthrough releases for its NBTXR3 platform, focusing on late-stage clinical trials. The dynamics of the total debt-to-equity ratio demonstrate the speed of balance sheet recovery, where the 0.00 parameter determines the metric's value. Cooperation with global oncology centers enhances radiation therapy, while a strategic alliance with Janssen and the influx of milestone payments ensure the biotech's financial stability.

NBTX: Rasio Total Utang marang Ekuitas Nanobiotix 04.07.2022 - 31.10.2026

Rincian metrik komprehensif lan analitis Nanobiotix Group (NBTX)

- rega lan prakiraan konsensus rega:
Bagan rega Nanobiotix|NBTX - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Nilai pasar Nanobiotix|NBTX - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Nanobiotix|NBTX - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku nanobiotix.com|NBTX - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Nanobiotix S.A.|NBTX - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Nanobiotix S.A.|NBTX - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Nanobiotix|NBTX - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Nanobiotix|Indikator likuiditas cepet nanobiotix.com
- informasi bathi lan kelipatan valuasi:
NBTX - Bathi pungkasan
Analisis fundamental perusahaan:Nanobiotix, NBTX
Barang utama Nanobiotix S.A.

The ratio is calculated as total liabilities divided by the company's equity. This metric determines the business's degree of dependence on borrowed funds and its financial stability risks. For Nanobiotix S.A. (NBTX), which is in the clinical development stage without stable revenue, this balance is critically important. The current value of 0.00 reflects the structure's dependence on external infusions. Analyzing the total debt-to-equity ratio allows for an assessment of the margin of safety prior to the commercialization of drugs.

Pesaing Nanobiotix S.A. (NBTX)

Utang marang Ekuitas Geron|Utang marang Modal Bicycle Therapeutics PLC BCYC|Utang marang Ekuitas CytomX Therapeutics Inc (CTMX)|perspectivetherapeutics.com - Rasio Utang marang Ekuitas|Total Utang marang Modal GNLX (Genelux)|MOLN - Rasio Total Utang marang Ekuitas|ONCY - Utang marang Ekuitas|Utang marang Modal Lisata Therapeutics|moleculin.com (MBRX) - Utang marang Ekuitas|GRTX (Galera Therapeutics, Inc.) - Utang marang Ekuitas|Utang marang Ekuitas Molecular Templates